Several lines of evidence have supported the role of immunological mechanisms in the
pathogenesis of multiple sclerosis (MS) and new immunomodulatory strategies for its
treatment, eg subcutaneous application of interferon (IFN)-β, have emerged. We
investigated the ability of peripheral blood mononuclear cells (PBMC) in 21 consecutive
patients with clinically definite MS to produce interferons and lymphokines in response to
viral or mitogenic stimulation. Ten patients showed clinical signs of disease activity (acute …